

1 Below Expectations	2 Improving	3 Meets Expectations	4 Exceeds Expectations			
1. ABM opened the discussion in a thoughtful, engaging manner and set clear expectations for the call.			1	2	3	4
2. ABM made effective use of probing questions to elicit customer sentiment and advance the discussion.			1	2	3	4
3. ABM was able to proficiently articulate the following applicable aspects of messaging for ALTUVIIIIO:			1	2	3	4
<b>Home:</b>			1	2	3	4
<ul style="list-style-type: none"> <li>The first in class, high sustained hemophilia A treatment that delivers more days near normal factor VIII activity levels</li> </ul>						
<b>Factor VIII Levels:</b>			1	2	3	4
<ul style="list-style-type: none"> <li>Factor VIII activity levels matter</li> <li>Is it time for a higher level of protection?</li> </ul>						
<b>PK/MOE:</b>			1	2	3	4
<ul style="list-style-type: none"> <li>Delivering more days near normal</li> <li>Normal to near-normal FVIII activity levels were also seen in the phase 3 XTEND-1 trial</li> <li>Achieving high sustained mean factor VIII levels (&gt;40%) for most of the week by overcoming the half-life limitations of vWF</li> </ul>						
<b>Study Design:</b>			1	2	3	4
<ul style="list-style-type: none"> <li>First-in-class ALTUVIIIIO: XTEND-1 and XTEND-Kids clinical trials</li> </ul>						
<b>Efficacy:</b>			1	2	3	4
<ul style="list-style-type: none"> <li>Effective bleed protection with ALTUVIIIIO prophylaxis</li> <li>Patients who switched to ALTUVIIIIO prophylaxis experienced significant reductions in ABR</li> <li>Proven joint bleed protection and improved joint health</li> <li>Most patients experienced <b>zero</b> bleeds when treated with prophylaxis</li> <li>Effective on-demand bleed management with only 1 infusion</li> <li>Pain and physical health scores from patient-reported outcomes</li> <li>XTEND-1 treatment preference: participant-reported outcomes</li> </ul>						

1 Below Expectations	2 Improving	3 Meets Expectations	4 Exceeds Expectations			
<b>Safety:</b>			1	2	3	4
• ALTUVIIIIO has an established safety profile						
<b>Dosing:</b>			1	2	3	4
• Simplicity in dosing						
<b>Patient Support:</b>			1	2	3	4
• ALTUVIIIIO patient support services • ALTUVIIIIO financial assistance						
<b>Important Safety Information (ISI)</b>			1	2	3	4
<b>Summary:</b>			1	2	3	4
• Delivering more days near normal (>40%) with once-weekly ALTUVIIIIO						